vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. USO
7. AMD
8. COHR
9. AMC
10. META

Go back to vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes
(NASDAQ: VTVT) Delayed: 31.30 -0.5 (1.57%)
Previous Close $31.80    52 Week High $7.70 
Open $31.45    52 Week Low $4.69 
Day High $32.00    P/E N/A 
Day Low $31.02    EPS $0.00 
Volume 22,687